Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zinc and cream combo may stop painful side effect of cancer treatment

NCT ID NCT06856590

Symptom relief Sponsor: Gazi University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested whether taking zinc supplements and applying a strong steroid cream (clobetasol) can prevent or reduce hand-foot skin reaction, a common and painful side effect of the cancer drug regorafenib. About 150 patients starting regorafenib were split into three groups: zinc plus cream, cream alone, or zinc alone. Researchers tracked how many developed severe skin reactions over 8 weeks, aiming to find a simple way to keep patients comfortable on treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
zinc gluconate and clobetasol propionate cream
What this could lead to
If it works, this could give cancer patients a simple way to avoid a painful side effect of regorafenib, helping them stay on treatment.
What could go wrong
This is a small, non-randomized study, so results may not be definitive. The treatments might not work for everyone or could cause their own side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

150 people

The number who actually took part.

Started

Feb 2025

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Histologically confirmed solid tumor for which regorafenib is an approved treatment (e.g., metastatic colorectal cancer, gastrointestinal stromal tumor, hepatocellular carcinoma, glioblastoma, or others) * Initiating regorafenib treatment for the first time * ECOG performance status of 0-2 * Baseline hand-foot skin reaction (HFSR) of Grade 0 (no prior HFSR symptoms) according to CTCAE v5.0 * Adequate organ function, including: AST/ALT ≤ 3× upper limit of normal (ULN) Creatinine clearance \> 50 mL/min Hemoglobin ≥ 9 g/dL Platelet count ≥ 75,000/mm³ * Able to tolerate oral zinc supplementation and/or topical corticosteroids * Willing to participate and provide informed consent Exclusion Criteria: * Pre-existing dermatologic conditions affecting the hands or feet (e.g., psoriasis, eczema, active infections) * Prior Grade ≥1 HFSR from any VEGFR-TKI therapy * Allergy or known hypersensitivity to zinc, clobetasol, or other study components

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glioblastoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm gastrointestinal stromal tumor glioblastoma hepatocellular carcinoma hand-foot syndrome prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hand-foot skin reaction (HFSR)

Contacts and locations

Locations

  • Afyonkarahisar University of Health Sciences Hospital

    Afyonkarahisar, 03030, Turkey (Türkiye)

  • Ankara Etlik City Hospital

    Ankara, Yenimahalle, 06170, Turkey (Türkiye)

  • Ankara University Faculty of Medicine Hospital

    Ankara, 06230, Turkey (Türkiye)

  • Bursa Uludağ University Hospital

    Bursa, Nilüfer, 16059, Turkey (Türkiye)

  • Dicle University Hospital

    Diyarbakır, 21280, Turkey (Türkiye)

  • Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital

    Ankara, Yenimahalle, 06200, Turkey (Türkiye)

  • Gazi University

    Ankara, Yenimahalle, 06500, Turkey (Türkiye)

  • Hacettepe University Faculty of Medicine Hospital

    Ankara, 06230, Turkey (Türkiye)

  • Karadeniz Technical University Hospital

    Trabzon, Ortahisar, 61080, Turkey (Türkiye)

  • Necmettin Erbakan University Meram Faculty of Medicine Hospital

    Konya, Meram, 42080, Turkey (Türkiye)

  • Sakarya University Hospital

    Sakarya, Serdivan, 54050, Turkey (Türkiye)

  • Tekirdağ Namık Kemal University Hospital

    Tekirdağ, 59100, Turkey (Türkiye)

  • Van Yüzüncü Yıl University Dursun Odabaş Hospital

    Van, 65080, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.